Eisai Co., Ltd.

Eisai develops, manufactures, and sells pharmaceuticals in Japan. Its operations are structured into pharmaceuticals business and business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy.

Its portfolio also includes LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils, and Dayvigo, a novel small molecule compound, as well as prescription drugs

Over-the-counter drugs, as well as focuses on neurology and oncology, and therapeutic areas. It operates globally. Incorporated in 1941 and headquartered in Tokyo, Japan, Eisai was formerly known as Nihon Eisai Co., Ltd. before rebranding in 1955.